Kristen Ahlschwede, PhD
In this section
Dr. Kristen Ahlschwede, Assistant Professor of Pharmaceutical Sciences, joined the college on July 1, 2015. Dr. Ahlschwede received her B.S. in biomedical sciences from the University of South Florida in 2007. She immediately went on to complete a master’s degree in pharmaceutical sciences in 2010 the College of Pharmacy and Pharmaceutical Sciences from Florida A&M University, followed by her PhD in pharmaceutical sciences from the same university in 2013. Dr. Ahlschwede completed her post-doctoral fellowship in pharmacokinetics at the College of Pharmacy at University of Minnesota where she evaluated the effect of insulin on amyloid clearance from the Alzheimer’s disease brain. She completed a second post-doctoral fellowship at the U.S. Food and Drug Administration, National Center for Toxicological Research.
Since 2007, I have been working in the research area of neurology, nanotechnology and nanomedicine. In the initial states of my career, I developed methods to enhance the stability of nanovehicles and developed various types of polymeric nanoparticles to treat and diagnose cerebral amyloid angiopathy. Other previous research projects that I have completed include, evaluating the effect of insulin on amyloid clearance from the Alzheimer’s disease brain and evaluating the effect of age on insulin trafficking into the central nervous system. Prior to joining RFUMS, I worked at the nanocore facility at the U.S. Food and Drug Administration, National Center for Toxicological Research on a research project targeted toward providing (FDA) reviewers with the necessary information to build more clinically relevant standards for FDA-regulated nanoparticulate drug products. My research areas of interest are nanotechnology, nanomedicine, delivery of therapeutic and diagnostic agents to the central nervous system, novel strategies to improve the uptake of nanoparticles at the blood brain barrier and pharmacokinetic data analysis and modeling.
Agyare E, Jaruszewski KM, Curran GL, Rosenberg JT, Grant SC, Lowe VJ, Ramakrishnan S, Paravastu A, Poduslo JF, Kandimalla KK. Engineering theranostic nanovehicles capable of targeting cerebrovascular amyloid deposits. Journal of Controlled Release, 2014, 185, 121-129, 2014.
Jaruszewski KM, Curran GL, Swaminathan SK, Rosenberg JT, Ramakrishnan S, Lowe VJ, Grant SC, Poduslo JF, Kandimalla KK. Multimodal nanoprobes to target cerebrovascular amyloid. Biomaterials, 35(6), 1967-76, 2014.
Jaruszewski KM, Ramakrishnan S, Poduslo JF, Kandimalla KK. Chitosan enhances the stability and targeting of immuno-nanovehicles to cerebro-vascular deposits of Alzheimer’s disease amyloid protein. Nanomedicine: Nanotechnology, Biology and Medicine, 8(2), 250-260, 2012.
Jaruszewski KM, Omtri RS, Kandimalla KK. Current advances in the medical application of nanotechnology: role of nanotechnology in the diagnosis and treatment of Alzheimer’s disease. Bentham Science Publishers, 2012.